Povorcitinib meets primary endpoint in two phase 3 vitiligo trials
The authors reported that povorcitinib 30 mg daily achieved ≥75% improvement in facial Vitiligo Area Scoring Index at week 52 in both STOP-V1 and STOP-V2, with 18.9% versus 6.8% and 18.9% versus 3.1% respectively. Treatment-emergent adverse events were similar to placebo, with 68.7%/66.7% versus 63.7%/62.7% and no class-specific serious events.
Primary source
PubMed record of a Phase III journal article, November 3, 2026
Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials.
Read the source: Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials. pubmed.ncbi.nlm.nih.gov
Machine-summarized from the source above; not independently reported. How we use automation